Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.
Menu

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates GlobeNewswire - Thu Aug 13, 3:20PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial  of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates GlobeNewswire - Thu Aug 13, 3:20PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --

GNLX : 2.62 (-1.69%)
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer GlobeNewswire - Tue Jun 30, 7:00AM CDT

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated...

GNLX : 2.62 (-1.69%)
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer GlobeNewswire - Tue Jun 30, 7:00AM CDT

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates GlobeNewswire - Thu May 7, 3:15PM CDT

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates GlobeNewswire - Thu May 7, 3:15PM CDT

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Mar 19, 3:15PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses...

GNLX : 2.62 (-1.69%)
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Mar 19, 3:15PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data...

GNLX : 2.62 (-1.69%)
Genelux Corporation to Participate in Upcoming Conferences GlobeNewswire - Wed Feb 18, 7:00AM CST

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in...

GNLX : 2.62 (-1.69%)
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners GlobeNewswire - Mon Jan 12, 3:00PM CST

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.62 (-1.69%)

Barchart Exclusives

AMD Stock Alert: Advanced Micro Devices Teams Up With Cisco on AI Infrastructure Barchart - 17 minutes ago
AMD stock gains after launching a new AI platform in Saudi Arabia in collaboration with Cisco. But does that warrant buying AMD shares? Let’s find out! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.